AIGH Capital Management LLC Has $17.26 Million Stock Holdings in Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC increased its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 33.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 2,000,000 shares of the company’s stock after buying an additional 500,000 shares during the quarter. Kyverna Therapeutics accounts for about 2.4% of AIGH Capital Management LLC’s investment portfolio, making the stock its 10th largest holding. AIGH Capital Management LLC’s holdings in Kyverna Therapeutics were worth $17,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KYTX. Adage Capital Partners GP L.L.C. acquired a new position in Kyverna Therapeutics in the fourth quarter valued at about $15,667,000. Balyasny Asset Management L.P. acquired a new stake in Kyverna Therapeutics during the fourth quarter worth about $9,220,000. Propel Bio Management LLC acquired a new stake in Kyverna Therapeutics during the fourth quarter worth about $6,267,000. Alyeska Investment Group L.P. bought a new position in Kyverna Therapeutics in the 4th quarter valued at about $5,640,000. Finally, RFG Advisory LLC bought a new position in Kyverna Therapeutics in the 4th quarter valued at about $4,185,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Stock Up 2.4%

Shares of KYTX opened at $9.91 on Thursday. Kyverna Therapeutics, Inc. has a 52 week low of $2.78 and a 52 week high of $13.67. The stock has a market capitalization of $602.43 million, a price-to-earnings ratio of -3.02 and a beta of 1.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15. The stock has a fifty day moving average of $8.69 and a 200-day moving average of $8.64.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. As a group, sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYTX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. decreased their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.